消息面上，同源康医药-B发布公告，于2025年7月28日，公司与配售代理订立配售协议，据此，配售代 理有条件同意作为公司的配售代理，按尽力基准促使承配人按每股配售股份17.01港元的配售价购买923 万股配售股份。 同源康医药-B(02410)涨超3%，截至发稿，涨2.34%，报21.85港元，成交额3234.21万港元。 假设所有配售股份获悉数配售及待完成后，预期配售事项所得款项总额及所得款项净额(经扣除配售佣 金及配售事项的其他相关成本及开支后)将分别约为1.57亿港元及1.55亿港元。按此基准，净发行价将约 为每股股份16.76港元。公司拟按如下方式分配配售事项所得款项净额(经扣除发行费用后)：配售事项所 得款项净额的约60%，用于现有管线的研发及商业化；配售事项所得款项净额的约30%，用于加强其内 部研发技术能力及扩展其产品组合；及配售事项所得款项净额的约10%，用于营运资金及一般企业用 途。 假设于本公告日期至交割日期期间已发行股份数目并无变动，则配售事项项下的923万股配售股份相当 于经配发及发行配售股份扩大后的已发行H股数目的约2.46%及已发行股份数目的约2.43%。每股配售股 份17.01港 ...

Group 1 - The core point of the news is that Tongyuan Kang Pharmaceutical-B (02410) has announced a placement agreement to issue 9.23 million shares at a price of HKD 17.01 per share, which represents a discount of approximately 19% compared to the last closing price of HKD 21.0 on July 28, 2025 [1][2] - The placement will result in an increase of approximately 2.46% in the total issued H-shares and about 2.43% in the total issued shares of the company [1] - The expected total proceeds from the placement are approximately HKD 157 million, with a net amount of about HKD 155 million after deducting commissions and related costs [2] Group 2 - The company plans to allocate approximately 60% of the net proceeds from the placement for research and commercialization of its existing pipeline [2] - About 30% of the net proceeds will be used to enhance internal research capabilities and expand the product portfolio [2] - The remaining 10% of the net proceeds will be allocated for working capital and general corporate purposes [2]